drugset / Trial / NCT00434135
Alimta and Gemcitabine in Non-Small Cell Lung Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
The aims of this study are: (1) to assess the safety and activity of gemcitabine plus Alimta (pemetrexed) regimen (GA regimen) in patients with advanced NSCLC patients in the context of a randomized trial, and (2) to compare the GA with the paclitaxel plus gemcitabine (PG regimen) in terms of toxicity and QoL
Timeline
- Start
- 2006-05
- Primary completion
- 2007-10
- Completion
- 2008-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | Intravenous |
| Subject | Gemcitabine | Small molecule | 1250 mg/m2 | Intravenous |
| Subject | Paclitaxel | Small molecule | 120 mg/m2 | — |
| Subject | Pemetrexed | Small molecule | 500 mg/m2 | Intravenous |